Thanks, reaper247. Easily the best post this month.
ONCX is a solid play with amazing ROI potential.
Oncolix's debt is relatively low compared to most clinical stage biopharma companies. All available information points toward Prolanta passing Phase I with no serious adverse events or dose-limiting toxicity as well as showing evidence of efficacy. Phase II clinical trials are all but guaranteed at this point.
To date, Redman has done an exemplary job by achieving solid milestones in a timely manner.
Frivolous attacks on the company, officers, and drug would be laughable if not so disgusting and evil in nature.
Thanks again for addressing the disingenuous alternative facts (blatant lies) being regurgitated on this thread.